$STRO
SUTRO BIOPHARMA, INC. Stock $stro

$stro Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000095017023010976 Filed on March 30, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$12.67M	$8.632M	$67.77M
YoY Change	114.92%	-18.98%	9.52%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$15.51M	$14.72M	$59.54M
YoY Change	3.15%	-6.62%	6.32%
% of Gross Profit
Research & Development	$39.40M	$43.14M	$137.2M
YoY Change	31.37%	44.13%	31.39%
% of Gross Profit
Depreciation & Amortization	$1.615M	$1.528M	$5.700M
YoY Change	21.7%	16.2%	18.75%
% of Gross Profit
Operating Expenses	$54.91M	$57.85M	$196.7M
YoY Change	21.95%	26.62%	22.64%
Operating Profit	-$42.24M		-$128.9M
YoY Change	7.93%		30.87%
Interest Expense	-$7.418M	$14.63M	$12.24M
YoY Change	-33818.18%	-573.55%	-274.49%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$49.66M	-$34.59M	-$116.7M
YoY Change	26.96%	-9.26%	10.58%
Income Tax	$400.0K	$0.00	$2.500M
% Of Pretax Income
Net Earnings	-$50.05M	-$34.59M	-$119.2M
YoY Change	27.97%	-9.26%	12.95%
Net Earnings / Revenue	-394.9%	-400.76%	-175.89%
Basic Earnings Per Share	-$0.85		-$2.35
Diluted Earnings Per Share	-$0.85	-$0.61	-$2.35
COMMON SHARES
Basic Shares Outstanding	60.16M	57.48M	50.74M
Diluted Shares Outstanding	58.72M		50.74M

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$276.5M	$334.4M	$334.4M
YoY Change	32.2%	68.92%	68.92%
Cash & Equivalents	$62.47M	$47.25M	$47.25M
Short-Term Investments	$214.0M	$287.1M	$287.1M
Other Short-Term Assets	$17.70M	$11.67M	$11.67M
YoY Change	123.69%	43.63%	43.63%
Inventory
Prepaid Expenses
Receivables	$9.873M	$7.122M	$7.122M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$304.1M	$353.2M	$353.2M
YoY Change	32.93%	61.61%	61.61%
LONG-TERM ASSETS
Property, Plant & Equipment	$24.03M	$24.62M	$51.06M
YoY Change	3.2%	9.18%	-1.02%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Other Assets	$3.250M	$1.855M	$2.727M
YoY Change	90.62%	12.08%	7.91%
Total Long-Term Assets	$53.95M	$53.79M	$53.79M
YoY Change	-28.0%	-56.23%	-56.23%
TOTAL ASSETS
Total Short-Term Assets	$304.1M	$353.2M	$353.2M
Total Long-Term Assets	$53.95M	$53.79M	$53.79M
Total Assets	$358.0M	$406.9M	$406.9M
YoY Change	17.89%	19.2%	19.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.058M	$4.797M	$4.797M
YoY Change	-52.75%	-57.65%	-57.65%
Accrued Expenses	$6.356M	$13.14M	$32.49M
YoY Change	17.53%	15.11%	160.89%
Deferred Revenue	$17.19M	$16.76M
YoY Change	173.71%	204.93%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$13.24M	$12.50M	$12.50M
YoY Change	5.94%	33.33%	33.33%
Total Short-Term Liabilities	$59.49M	$66.55M	$66.55M
YoY Change	53.47%	59.45%	59.45%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$3.771M	$3.771M
YoY Change	-100.0%	-76.04%	-76.04%
Other Long-Term Liabilities	$113.1M	$119.0K	$119.6M
YoY Change	76850.34%	-18.49%	281.19%
Total Long-Term Liabilities	$113.1M	$3.890M	$123.3M
YoY Change	776.26%	-75.51%	161.84%
TOTAL LIABILITIES
Total Short-Term Liabilities	$59.49M	$66.55M	$66.55M
Total Long-Term Liabilities	$113.1M	$3.890M	$123.3M
Total Liabilities	$172.6M	$189.9M	$189.9M
YoY Change	107.2%	113.74%	113.74%
SHAREHOLDERS EQUITY
Retained Earnings	-$502.7M	-$452.6M
YoY Change	34.95%	35.75%
Common Stock	$688.2M	$670.3M
YoY Change	15.85%	14.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$185.4M	$217.0M	$217.0M
YoY Change
Total Liabilities & Shareholders Equity	$358.0M	$406.9M	$406.9M
YoY Change	17.89%	19.2%	19.2%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$50.05M	-$34.59M	-$119.2M
YoY Change	27.97%	-9.26%	12.95%
Depreciation, Depletion And Amortization	$1.615M	$1.528M	$5.700M
YoY Change	21.7%	16.2%	18.75%
Cash From Operating Activities	-$60.99M	-$23.86M	$3.549M
YoY Change	73.0%	10.58%	-104.35%
INVESTING ACTIVITIES
Capital Expenditures	$942.0K	$3.367M	$7.858M
YoY Change	-160.66%	-232.72%	-151.28%
Acquisitions
YoY Change
Other Investing Activities	$68.39M	-$34.52M	-$27.16M
YoY Change	98.04%	-248.02%	-66.87%
Cash From Investing Activities	$67.45M	-$37.88M	-$35.02M
YoY Change	104.51%	-282.29%	-64.01%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$56.27M
YoY Change			803757.14%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	8.758M	12.22M	48.31M
YoY Change	1052.37%	2315.22%	1383.81%
NET CHANGE
Cash From Operating Activities	-60.99M	-23.86M	3.549M
Cash From Investing Activities	67.45M	-37.88M	-35.02M
Cash From Financing Activities	8.758M	12.22M	48.31M
Net Change In Cash	15.22M	-49.53M	16.84M
YoY Change	-1105.82%	16802.73%	-109.58%
FREE CASH FLOW
Cash From Operating Activities	-$60.99M	-$23.86M	$3.549M
Capital Expenditures	$942.0K	$3.367M	$7.858M
Free Cash Flow	-$61.93M	-$27.23M	-$4.309M
YoY Change	83.77%	43.0%	-93.51%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001382101
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-38662
CY2022	dei	Entity Registrant Name EntityRegistrantName	SUTRO BIOPHARMA, INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-0926186
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	111 Oyster Point Blvd
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	South San Francisco
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94080
CY2022	dei	City Area Code CityAreaCode	650
CY2022	dei	Local Phone Number LocalPhoneNumber	881-6500
CY2022	dei	Security12b Title Security12bTitle	Common stock, $0.001 par value
CY2022	dei	Trading Symbol TradingSymbol	STRO
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	250700000
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	60160551
CY2022	dei	Auditor Firm AuditorFirmId	42
CY2022	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2022	dei	Auditor Location AuditorLocation	San Mateo, California
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	47254000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	30414000
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	255090000
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	130343000
CY2022Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	32020000
CY2021Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	37181000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	7122000
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	12454000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11667000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8123000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	353153000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	218515000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	24621000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	22550000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	26443000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	29041000
CY2021Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	68775000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1855000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1655000
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	872000
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	872000
CY2022Q4	us-gaap	Assets Assets	406944000
CY2021Q4	us-gaap	Assets Assets	341408000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4797000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6009000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13142000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11417000
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	16759000
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	5496000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4585000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1037000
CY2022Q4	us-gaap	Debt Current DebtCurrent	12500000
CY2021Q4	us-gaap	Debt Current DebtCurrent	9375000
CY2022Q4	stro	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	14764000
CY2021Q4	stro	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	8402000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	66547000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	41736000
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	89885000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	29574000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	31224000
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	3771000
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	15738000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	119000
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	146000
CY2022Q4	us-gaap	Liabilities Liabilities	189896000
CY2021Q4	us-gaap	Liabilities Liabilities	88844000
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	57499541
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	57499541
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	46327131
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	46327131
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	58000
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	46000
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	670223000
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	586243000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-618000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-314000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-452615000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-333411000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	217048000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	252564000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	406944000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	341408000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	67772000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	61880000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	42722000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	137171000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	104400000
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	76961000
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	59544000
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	56004000
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	36818000
CY2022	us-gaap	Operating Expenses OperatingExpenses	196715000
CY2021	us-gaap	Operating Expenses OperatingExpenses	160404000
CY2020	us-gaap	Operating Expenses OperatingExpenses	113779000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-128943000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-98524000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-71057000
CY2022	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	3455000
CY2021	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	577000
CY2020	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	1508000
CY2022	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	12130000
CY2021	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-4454000
CY2020	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	41498000
CY2022	stro	Interest And Other Income Expense Net InterestAndOtherIncomeExpenseNet	-3346000
CY2021	stro	Interest And Other Income Expense Net InterestAndOtherIncomeExpenseNet	-3137000
CY2020	stro	Interest And Other Income Expense Net InterestAndOtherIncomeExpenseNet	-3974000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-116704000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-105538000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-32025000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2500000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	103000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-119204000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-105538000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-32128000
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.35
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.35
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.29
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.29
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.99
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.99
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	50739185
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	50739185
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	46119089
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	46119089
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32573469
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	32573469
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-119204000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-105538000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-32128000
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-304000
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-443000
CY2020	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-36000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-119508000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-105981000
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-32164000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	97789000
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1861000
CY2020	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1285000
CY2020	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	314000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	11917000
CY2020	stro	Warrants Issued During Period Value In Connection With Debt Refinancing WarrantsIssuedDuringPeriodValueInConnectionWithDebtRefinancing	619000
CY2020	stro	Common Stock Issuance Costs CommonStockIssuanceCosts	15686000
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	227252000
CY2020	stro	Stock Issued During Period Value Through At The Market Sale StockIssuedDuringPeriodValueThroughAtTheMarketSale	23803000
CY2020	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-36000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-32128000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	332048000
CY2021	stro	Stock Issued During Period Value Stock Options And Warrants Exercised StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised	2485000
CY2021	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	7000
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1765000
CY2021	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	987000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	23241000
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-443000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-105538000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	252564000
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	268000
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1613000
CY2022	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	463000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	26304000
CY2022	stro	Stock Issued During Period Value Through At The Market Sale StockIssuedDuringPeriodValueThroughAtTheMarketSale	56270000
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-304000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-119204000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	217048000
CY2022	us-gaap	Profit Loss ProfitLoss	-119204000
CY2021	us-gaap	Profit Loss ProfitLoss	-105538000
CY2020	us-gaap	Profit Loss ProfitLoss	-32128000
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5690000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4844000
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4297000
CY2022	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	364000
CY2021	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-2781000
CY2020	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	490000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	26304000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	23241000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	11917000
CY2022	stro	Noncash Lease Expenses NoncashLeaseExpenses	2598000
CY2021	stro	Noncash Lease Expenses NoncashLeaseExpenses	4929000
CY2022	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	4074000
CY2022	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	12130000
CY2021	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-4454000
CY2020	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	41498000
CY2022	stro	Remeasurement Of Liability Awards RemeasurementOfLiabilityAwards	2000
CY2021	stro	Remeasurement Of Liability Awards RemeasurementOfLiabilityAwards	12000
CY2020	stro	Remeasurement Of Liability Awards RemeasurementOfLiabilityAwards	-19000
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-326000
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-1242000
CY2020	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-587000
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-5341000
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	6895000
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-739000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3544000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3959000
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	80000
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1225000
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2708000
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1141000
CY2022	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	1725000
CY2021	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	2594000
CY2020	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	2806000
CY2022	stro	Increase Decrease In Accrued Expenses And Other Liabilities IncreaseDecreaseInAccruedExpensesAndOtherLiabilities	6562000
CY2021	stro	Increase Decrease In Accrued Expenses And Other Liabilities IncreaseDecreaseInAccruedExpensesAndOtherLiabilities	5866000
CY2020	stro	Increase Decrease In Accrued Expenses And Other Liabilities IncreaseDecreaseInAccruedExpensesAndOtherLiabilities	216000
CY2020	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	-931000
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	93648000
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-15207000
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-14957000
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	1898000
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-2727000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	3549000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-81679000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-67802000
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	216671000
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	248727000
CY2020	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	130741000
CY2022	stro	Proceeds From Maturities Of Marketable Securities ProceedsFromMaturitiesOfMarketableSecurities	127960000
CY2021	stro	Proceeds From Maturities Of Marketable Securities ProceedsFromMaturitiesOfMarketableSecurities	148250000
CY2020	stro	Proceeds From Maturities Of Marketable Securities ProceedsFromMaturitiesOfMarketableSecurities	116385000
CY2022	stro	Proceeds From Sales Of Marketable Securities ProceedsFromSalesOfMarketableSecurities	32799000
CY2021	stro	Proceeds From Sales Of Marketable Securities ProceedsFromSalesOfMarketableSecurities	18476000
CY2020	stro	Proceeds From Sales Of Marketable Securities ProceedsFromSalesOfMarketableSecurities	22000000
CY2022	us-gaap	Proceeds From Sale Of Equity Securities Fv Ni ProceedsFromSaleOfEquitySecuritiesFvNi	28739000
CY2022	stro	Payments To Acquire Equipment And Leasehold Improvements PaymentsToAcquireEquipmentAndLeaseholdImprovements	7858000
CY2021	stro	Payments To Acquire Equipment And Leasehold Improvements PaymentsToAcquireEquipmentAndLeaseholdImprovements	15323000
CY2020	stro	Payments To Acquire Equipment And Leasehold Improvements PaymentsToAcquireEquipmentAndLeaseholdImprovements	7129000
CY2022	stro	Proceeds From Exercise Of Options For Vaxcyte Shares ProceedsFromExerciseOfOptionsForVaxcyteShares	9000
CY2021	stro	Proceeds From Exercise Of Options For Vaxcyte Shares ProceedsFromExerciseOfOptionsForVaxcyteShares	9000
CY2020	stro	Proceeds From Exercise Of Options For Vaxcyte Shares ProceedsFromExerciseOfOptionsForVaxcyteShares	89000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-35022000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-97315000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	604000
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	56270000
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	251415000
CY2020	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	25000000
CY2022	us-gaap	Repayments Of Debt RepaymentsOfDebt	9375000
CY2020	us-gaap	Repayments Of Debt RepaymentsOfDebt	10000000
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	268000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2485000
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1861000
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	463000
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	987000
CY2020	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	314000
CY2021	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	7000
CY2022	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1613000
CY2021	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1765000
CY2020	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1285000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	48313000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3256000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	269247000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	16840000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-175738000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	202049000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	31286000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	207024000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4975000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	48126000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	31286000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	207024000
CY2022	us-gaap	Interest Paid Net InterestPaidNet	1869000
CY2021	us-gaap	Interest Paid Net InterestPaidNet	2046000
CY2020	us-gaap	Interest Paid Net InterestPaidNet	1675000
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	103000
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	280000
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	370000
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	546000
CY2021	stro	Remeasurement Of Operating Lease Right Of Use Assets For Lease Modification RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification	4227000
CY2020	stro	Offering Costs Included In Accounts Payable OfferingCostsIncludedInAccountsPayable	361000
CY2022	stro	Financing Component Associated With Program Fees FinancingComponentAssociatedWithProgramFees	5079000
CY2021	stro	Financing Component Associated With Program Fees FinancingComponentAssociatedWithProgramFees	610000
CY2020	stro	Financing Component Associated With Program Fees FinancingComponentAssociatedWithProgramFees	1852000
CY2022	stro	Stock Received During Period Shares StockReceivedDuringPeriodShares	167780
CY2021	stro	Stock Received During Period Shares StockReceivedDuringPeriodShares	167780
CY2020	stro	Stock Received During Period Shares StockReceivedDuringPeriodShares	167780
CY2022Q4	us-gaap	Investment Owned At Fair Value InvestmentOwnedAtFairValue	7500000
CY2020	stro	Warrants Issued To Lenders WarrantsIssuedToLenders	619000
CY2022	us-gaap	Nature Of Operations NatureOfOperations	<p style="text-indent:2.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Arial", sans-serif;min-width:fit-content;">1. Organization and Principal Activities</span></p><p style="text-indent:2.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Arial", sans-serif;font-style:italic;min-width:fit-content;">Description of Business</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Arial", sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.4%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Arial", sans-serif;min-width:fit-content;">Sutro Biopharma, Inc. (the “Company”), is a clinical-stage oncology company developing site-specific and novel-format antibody drug conjugates, or ADCs. The Company was incorporated on </span><span style="font-size:10.0pt;font-family:"Arial", sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Arial", sans-serif;min-width:fit-content;">April 21, 2003</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Arial", sans-serif;min-width:fit-content;"> and is headquartered in </span><span style="font-size:10.0pt;font-family:"Arial", sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Arial", sans-serif;min-width:fit-content;">South San Francisco</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Arial", sans-serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:"Arial", sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Arial", sans-serif;min-width:fit-content;">California</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Arial", sans-serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Arial", sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:3.4%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Arial", sans-serif;min-width:fit-content;">The Company operates in </span><span style="font-size:10.0pt;font-family:"Arial", sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Arial", sans-serif;min-width:fit-content;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Arial", sans-serif;min-width:fit-content;"> business segment, the development of biopharmaceutical products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Arial", sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:2.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Arial", sans-serif;font-style:italic;min-width:fit-content;">At-The-Market Sales</span></p><p style="text-indent:3.4%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Arial", sans-serif;min-width:fit-content;">During the year ended December 31, 2022, the Company sold an aggregate of </span><span style="font-size:10.0pt;font-family:"Arial", sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Arial", sans-serif;min-width:fit-content;">10,285,160</span><span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Arial", sans-serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Arial", sans-serif;min-width:fit-content;">shares of its common stock through its At-the-Market Facility (“ATM Facility”) pursuant to its Open Market Sales Agreement</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:"Arial", sans-serif;min-width:fit-content;">SM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Arial", sans-serif;min-width:fit-content;"> dated April 2, 2021 with Jefferies LLC (“Jefferies”), as sales agent (the “Sales Agreement”).</span></p><p style="text-indent:3.4%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Arial", sans-serif;min-width:fit-content;">During the year ended December 31, 2022, the gross proceeds from these sales were approximately $</span><span style="font-size:10.0pt;font-family:"Arial", sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Arial", sans-serif;min-width:fit-content;">58.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Arial", sans-serif;min-width:fit-content;"> million, before deducting fees of approximately $</span><span style="font-size:10.0pt;font-family:"Arial", sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Arial", sans-serif;min-width:fit-content;">2.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Arial", sans-serif;min-width:fit-content;"> million, resulting in net proceeds of approximately $</span><span style="font-size:10.0pt;font-family:"Arial", sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Arial", sans-serif;min-width:fit-content;">56.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Arial", sans-serif;min-width:fit-content;"> million, to the Company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Arial", sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:2.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Arial", sans-serif;font-style:italic;min-width:fit-content;">Liquidity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Arial", sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.4%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Arial", sans-serif;min-width:fit-content;">The Company has incurred significant losses to date and had negative cash flows from operations in the years prior to the year ended December 31, 2022. As of December 31, 2022, there was an accumulated deficit of $</span><span style="font-size:10.0pt;font-family:"Arial", sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Arial", sans-serif;min-width:fit-content;">452.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Arial", sans-serif;min-width:fit-content;"> million. Management expects to continue to incur additional </span><span style="font-size:10.0pt;font-family:"Arial", sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Arial", sans-serif;min-width:fit-content;">substantial</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Arial", sans-serif;min-width:fit-content;"> losses in the foreseeable future as a result of the Company’s research and development and other operational activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Arial", sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:3.4%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Arial", sans-serif;min-width:fit-content;">As of December 31, 2022, the Company had unrestricted cash, cash equivalents and marketable securities of $</span><span style="font-size:10.0pt;font-family:"Arial", sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Arial", sans-serif;min-width:fit-content;">302.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Arial", sans-serif;min-width:fit-content;"> million and equity securities of $</span><span style="font-size:10.0pt;font-family:"Arial", sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Arial", sans-serif;min-width:fit-content;">32.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Arial", sans-serif;min-width:fit-content;"> million, consisting solely of common stock of Vaxcyte, which are available to fund future operations. The Company will need to raise additional capital to support the completion of its research and development activities and to support its operations.</span></p><p style="text-indent:3.4%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Arial", sans-serif;min-width:fit-content;">The Company believes that its unrestricted cash, cash equivalents, marketable securities and equity securities as of December 31, 2022 will enable the Company to maintain its operations for a period of at least </span><span style="font-size:10.0pt;font-family:"Arial", sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Arial", sans-serif;min-width:fit-content;">12</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Arial", sans-serif;min-width:fit-content;"> months following the filing date of these financial statements.</span></p>
CY2022	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	2003-04-21
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	South San Francisco
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-452600000
CY2022	us-gaap	Substantial Doubt About Going Concern Within One Year SubstantialDoubtAboutGoingConcernWithinOneYear	false
CY2022Q4	stro	Unrestricted Cash Cash Equivalents And Marketable Securities At Carrying Value UnrestrictedCashCashEquivalentsAndMarketableSecuritiesAtCarryingValue	302300000
CY2022	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="text-indent:2.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Arial", sans-serif;font-style:italic;min-width:fit-content;">Prior Period Reclassifications</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Arial", sans-serif;min-width:fit-content;">The prior period presentation of interest and other income (expense), net and provision for income taxes have been updated to conform to current period presentation. The reclassifications had no effect on prior years' net loss.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Arial", sans-serif;min-width:fit-content;">The prior period presentation of accounts payable and accrued expenses and other current liabilities have been updated to conform to current period presentation. Accordingly, adjustments have been made to the Balance Sheets and Statements of Cash Flows. The reclassifications had no effect on </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Arial", sans-serif;min-width:fit-content;">prior years' net loss.</span></p>
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	900000
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	900000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	47254000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	30414000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	206152000
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	872000
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	872000
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	872000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	48126000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	31286000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	207024000
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="text-indent:2.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Arial", sans-serif;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Arial", sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.4%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Arial", sans-serif;min-width:fit-content;">Cash and cash equivalents and marketable securities consist of financial instruments that potentially subject the Company to a concentration of credit risk, to the extent of the amounts recorded on the Balance Sheets. The Company minimizes the amount of credit exposure by investing cash that is not required for immediate operating needs in money market funds, government obligations and/or commercial paper with short maturities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Arial", sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:3.4%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Arial", sans-serif;min-width:fit-content;">The Company performs a regular review of its collaborators’ credit risk and payment histories when circumstances warrant, including payments made subsequent to year-end. When appropriate, the Company provides for an allowance for credit risks by reserving for specifically identified doubtful accounts, although historically the Company has not experienced credit losses from its accounts receivable</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Arial", sans-serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Arial", sans-serif;min-width:fit-content;"> </span></p>
CY2022	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings	0
CY2021	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings	0
CY2020	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings	0
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0
CY2022	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0
CY2021	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0
CY2020	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	299026000
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	10000
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	626000
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	298410000
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	228883000
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	314000
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	228569000
CY2022Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	0
CY2021Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	68800000
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	139500000
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	176500000
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	600000
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	300000
CY2022Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	16800000
CY2022Q4	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P12M
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	62526000
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	55976000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	37905000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	33426000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	24621000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	22550000
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5700000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4800000
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4300000
CY2022Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	100000
CY2021Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	200000
CY2022	us-gaap	Interest Expense Debt InterestExpenseDebt	2400000
CY2021	us-gaap	Interest Expense Debt InterestExpenseDebt	2600000
CY2020	us-gaap	Interest Expense Debt InterestExpenseDebt	2300000
CY2022	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.0872
CY2021	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.0807
CY2020	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.0808
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	500000
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	600000
CY2020	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	500000
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	15625000
CY2021Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	25000000
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	-646000
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	-113000
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	16271000
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	25113000
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	12500000
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	9375000
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	3771000
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	15738000
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	13312000
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	4126000
CY2022Q4	stro	Debt Instrument Including Interest And Final Payment DebtInstrumentIncludingInterestAndFinalPayment	17438000
CY2022Q4	stro	Debt Instrument Interest Payable DebtInstrumentInterestPayable	855000
CY2022Q4	stro	Debt Instrument Final Payment DebtInstrumentFinalPayment	958000
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	15625000
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	6154000
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	8355000
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	82000
CY2021	us-gaap	Short Term Lease Cost ShortTermLeaseCost	117000
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	1610000
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	2089000
CY2022	us-gaap	Lease Cost LeaseCost	7846000
CY2021	us-gaap	Lease Cost LeaseCost	10561000
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	6200000
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	8400000
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	1700000
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	6200000
CY2020	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	4700000
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y9M18D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y8M12D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.108
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.108
CY2022	us-gaap	Common Stock Voting Rights CommonStockVotingRights	one vote per share
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.03
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	8002000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	9219000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	9533000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	8994000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	8289000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	44037000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	9878000
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	34159000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4585000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	29574000
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3080000
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2750000
CY2022Q4	stro	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	14764000
CY2021Q4	stro	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	8402000
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	13804406
CY2021Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	11221420
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	100000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	2800000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1200000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.818
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.835
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.809
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.849
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.732
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.874
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.017
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.042
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.006
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.013
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.002
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.016
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	14.24
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.59
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	26304000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	23241000
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11917000
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	103000
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	2500000
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	2500000
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	103000
CY2022	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	2500000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.001
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.262
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.247
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.347
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.051
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.037
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.093
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.032
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.002
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.019
CY2022	stro	Effective Income Tax Rate Reconciliation Foreign Tax Withholding EffectiveIncomeTaxRateReconciliationForeignTaxWithholding	-0.021
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.033
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.002
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.061
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.021
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.003
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	60952000
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	67719000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	40396000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	31864000
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	24481000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	3849000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	3973000
CY2022Q4	stro	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	7471000
CY2021Q4	stro	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	7266000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	4562000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3910000
CY2022Q4	stro	Deferred Tax Assets Fixed Assets DeferredTaxAssetsFixedAssets	663000
CY2021Q4	stro	Deferred Tax Assets Fixed Assets DeferredTaxAssetsFixedAssets	1008000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	142374000
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	115740000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	131228000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	100646000
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	11146000
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	15094000
CY2022Q4	stro	Deferred Tax Liabilities Operating Lease Right Of Use Asset DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset	5783000
CY2021Q4	stro	Deferred Tax Liabilities Operating Lease Right Of Use Asset DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset	6716000
CY2022Q4	us-gaap	Deferred Tax Liabilities Investments DeferredTaxLiabilitiesInvestments	5363000
CY2021Q4	us-gaap	Deferred Tax Liabilities Investments DeferredTaxLiabilitiesInvestments	8378000
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	11146000
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	15094000
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	30600000
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	26200000
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	11100000
CY2022	us-gaap	Operating Loss Carryforwards Limitations On Use OperatingLossCarryforwardsLimitationsOnUse	Events which cause limitations in the amount of net operating losses that the Company may utilize in any one year include, but are not limited to, a cumulative ownership change of more than 50%, as defined, over a three-year testing period.
CY2022	stro	Period For Cumulative Ownership Change PeriodForCumulativeOwnershipChange	P3Y
CY2022Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	8600000
CY2021Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	6400000
CY2020Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	4900000
CY2022	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	6409000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4902000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3783000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	2255000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1492000
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1090000
CY2022	stro	Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions	15000
CY2021	stro	Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions	15000
CY2020	stro	Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions	29000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	8649000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	6409000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4902000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-119204000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-105538000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-32128000
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	50739185
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	50739185
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	46119089
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	46119089
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32573469
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	32573469
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.35
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.35
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.29
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.29
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.99
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.99
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11547237
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9098287
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6314039

Files In Submission

Name	View Source	Status
0000950170-23-010976-index-headers.html	Edgar Link	pending
0000950170-23-010976-index.html	Edgar Link	pending
0000950170-23-010976.txt	Edgar Link	pending
0000950170-23-010976-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img140628684_0.jpg	Edgar Link	pending
img140628684_1.jpg	Edgar Link	pending
img140628684_2.jpg	Edgar Link	pending
img140628684_3.jpg	Edgar Link	pending
img140628684_4.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
stro-20221231.htm	Edgar Link	pending
stro-20221231.xsd	Edgar Link	pending
stro-ex10_35.htm	Edgar Link	pending
stro-ex23_1.htm	Edgar Link	pending
stro-ex31_1.htm	Edgar Link	pending
stro-ex31_2.htm	Edgar Link	pending
stro-ex32_1.htm	Edgar Link	pending
stro-ex32_2.htm	Edgar Link	pending
stro-20221231_def.xml	Edgar Link	unprocessable
stro-20221231_cal.xml	Edgar Link	unprocessable
stro-20221231_lab.xml	Edgar Link	unprocessable
stro-20221231_pre.xml	Edgar Link	unprocessable
stro-20221231_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$STRO
SUTRO BIOPHARMA, INC. Stock $stro

2023 Q1 Form 10-K Financial Statement

#000095017023010976 Filed on March 30, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$STRO SUTRO BIOPHARMA, INC. Stock $stro

2023 Q1 Form 10-K Financial Statement

#000095017023010976 Filed on March 30, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$STRO
SUTRO BIOPHARMA, INC. Stock $stro